varlilumab manufacturers
- Varlilumab
-
- $222.00
-
2026-07-27
- CAS:1393344-72-3
- Purity: 98.65% (SEC-HPLC)
- Supply Ability: 10g
|
| | varlilumab Basic information |
| Product Name: | varlilumab | | Synonyms: | varlilumab;Research Grade Varlilumab(DHD72201);Varlilumab (anti-TNFRSF7);CDX-1127;Research Grade Varlilumab | | CAS: | 1393344-72-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![varlilumab Structure]() |
| | varlilumab Chemical Properties |
| storage temp. | Store at -80°C | | form | Lyophilized Powder | | color | White to off-white |
| | varlilumab Usage And Synthesis |
| Uses | Varlilumab (CDX-1127) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity[1]. | | References | [1] Stephen M Ansell, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Adv. 2020 May 12;4(9):1917-1926. DOI:10.1182/bloodadvances.2019001079 |
| | varlilumab Preparation Products And Raw materials |
|